P-058 Depression and Anxiety in Inflammatory Bowel Disease

Neuendorf, Rachel; Aubrey, Harding; Stello, Noelle; Hanes, Doug; Wahbeh, Helané

doi:10.1097/01.mib.0000456795.55208.31

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ulcerative colitis (UC) is a chronic nonspecific inflammatory disease involving the colon and rectum [ 1 , 2 ], and its pathogenesis may result from changes in the colonic environment and the patients' psychological state [ 3 – 5 ]. Because the etiology and pathogenesis of the disease have not been fully elucidated, the recurrence, delayed healing course, and lack of specificity in treatment have brought mental and psychological pressure to patients.…”

Section: Introductionmentioning

confidence: 99%

The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis

Zhou

Zhao

Yang

et al. 2019

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Objectives. Our aim of this study is to compare the efficacy of flupentixol-melitracen in the adjuvant therapy of ulcerative colitis patients in the Chinese population. Methods. Both the RevMan 5.2 and the Stata 12.0 software are used in this study for analysis, and a fixed-effect model (the Mantel-Haenszel method) or a random-effect model (the DerSimonian and Laird method) is used to merge or aggregate the risk ratio (RR) and its 95% confidence intervals (CI) of included studies. Results. Eleven trials involving 654 ulcerative colitis patients (treated group: 328; control group: 326) were analyzed in this study. Significant differences (RR=1.29, 95% CI=1.20 to 1.40, P<0.001) between patients were observed between the two groups. Conclusions. Our results suggested that the efficacy of flupentixol-melitracen in the adjuvant therapy of ulcerative colitis is better than traditional drug treatments.

show abstract